SCHEMBL5124321

SCHEMBL5124321

O=C(Nc1ccccc1)c1ccccc1NC(=O)c1cc(Cl)ccc1NS(=O)(=O)c1ccc(Cl)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.66
KMT2A Q03164 5/20 0.66
KDM4E B2RXH2 2/20 0.66
SLC10A6 Q3KNW5 2/20 0.65
SLC10A2 Q12908 1/20 0.65
SLC10A1 Q14973 1/20 0.65
GPR27 Q9NS67 9/20 0.62
KCNA5 P22460 1/20 0.62
AVPR2 P30518 2/20 0.61
LMNA P02545 3/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
MAPT P10636 1/20 0.56
BDKRB1 P46663 1/20 0.55
HTT P42858 2/20 0.55
ALDH1A1 P00352 1/20 0.55
CYP3A4 P08684 1/20 0.55
CYP2D6 P10635 1/20 0.55
CYP2C9 P11712 1/20 0.55
HPGD P15428 1/20 0.55
CRHBP P24387 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5125081 0.91 KCNA5 (0.65) MEN1KMT2ASLC10A6SLC10A2SLC10A1
SCHEMBL5125757 0.90 SLC10A6 (0.69) MEN1KMT2AKDM4ESLC10A6SLC10A2
SCHEMBL6754585 0.88 SLC10A6 (0.81) MEN1KMT2AKDM4ESLC10A6SLC10A2
Thioglycolic Acid SCHEMBL491985 0.88 KCNA5 (0.64) MEN1KMT2AKDM4ESLC10A6SLC10A2
SCHEMBL5114776 0.87 SLC10A6 (0.62) MEN1KMT2AKDM4ESLC10A6SLC10A2
SCHEMBL6760783 0.86 SLC10A6 (0.74) MEN1KMT2AKDM4ESLC10A6SLC10A2
SCHEMBL5126770 0.86 SLC10A6 (0.67) MEN1KMT2AKDM4ESLC10A6SLC10A2
Benzene SCHEMBL490520 0.85 SLC10A6 (0.69) MEN1KMT2AKDM4ESLC10A6SLC10A2
SCHEMBL6182984 0.85 SLC10A6 (0.78) KMT2ASLC10A6SLC10A2SLC10A1KCNA5
SCHEMBL492118 0.84 SLC10A6 (0.65) MEN1KMT2AKDM4ESLC10A6SLC10A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7351703-B2 Sulfonylamino carboxylic acid N-arylamides as guanylate cyclase activators SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-04-01 US disclosed
EP-1095015-B1 SULFONYLAMINO CARBOXYLIC ACID N-ARYLAMIDES AS GUANYLATE CYCLASE ACTIVATORS AVENTIS PHARMA GMBH (DE) 2005-06-01 EP disclosed
US-20050080073-A1 Sulfonylaminocarboxiylic acid N-arylamides as guanylate cyclase activators AVENTIS PHARMA DEUTSCHLAND GMBH 2005-04-14 US disclosed
US-6809089-B2 FOR THERAPY AND PROPHYLAXIS OF CARDIOVASCULAR DISORDERS SUCH AS HIGH BLOOD PRESSURE, ANGINA PECTORIS, CARDIAC INSUFFICIENCY, THROMBOSES OR ATHEROSCLEROSIS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-10-26 US disclosed
US-20030171352-A1 Sulfonylaminocarboxylic acid N-arylamides as guanylate cyclase activators AVENTIS PHARMA DEUTSCHLAND GMBH 2003-09-11 US disclosed
US-6548547-B1 Cardiovascular disorders; hypotensive agents, antiasthmatics, cognition activators AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2003-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080073-A1 Sulfonylaminocarboxiylic acid N-arylamides as guanylate cyclase activators GUCY1A1, GUCY1B1, GUCY1A2 MEN1 3114/4885KMT2A 3785/4885KDM4E 4187/4885
US-20030171352-A1 Sulfonylaminocarboxylic acid N-arylamides as guanylate cyclase activators GUCY1A1, GUCY1B1, GUCY1B2 MEN1 3892/4885KMT2A 4155/4885KDM4E 3666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.